SARS-CoV-2 Saliva Test
The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Rutgers’ RUCDR Infinite Biologics and its collaborators for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus. Developed in partnership with Spectrum Solutions and Accurate Diagnostic Labs (ADL) and as of April 16, 2020, only available in the state of New Jersey. Public expansion is expected to begin in May 2020.
Availability: Commercially Available
Professor Andrew Brooks
Chief Operating Officer and Director of Technology Development at RUCDR Infinite Biologics, Rutgers
+1 848 445 4636
57 US Highway 1
New Brunswick, NJ 08901-8554
USA
|
|
www.rutgers.edu
| Manufacturer |
| Rutgers University |
| Product Name |
| SARS-CoV-2 Saliva Test |
| Detection Category |
| Biological |
| Detection Principle |
| Molecular; |
| Detection Method |
| Assays; |
| Application |
| Diagnostics; |
| Equipment Type |
| Diagnostic |
| Product Synopsis |
| The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Rutgers’ RUCDR Infinite Biologics and its collaborators for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus. Developed in partnership with Spectrum Solutions and Accurate Diagnostic Labs (ADL) and as of April 16, 2020, only available in the state of New Jersey. Public expansion is expected to begin in May 2020. |
| Availability |
| Commercially Available |
| Technology Readiness Level (TRL) |
| 8 |
| Market Entry Date |
| April 2020 |
| User Feedback Sources |
| Indifferent/No user feedback |
| No Information Is Available |
| Transportability |
| Pocket Size |
| Other Biological Targets |
| SARS-CoV-2 |
| Sample Introduction |
| Liquid; Biological sample |
| Training Required |
| <1 day training |
